Burrill Starts Prana Biotechnology (PRAN) at Market Outperform
Tweet
Share
E-mailGet Alerts PRAN Hot Sheet
Price: $2.06 --0%
Rating Summary:
1 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 5
Rating Summary:
1 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 5
Join SI Premium – FREE
Burrill initiates coverage on Prana Biotechnology (NASDAQ: PRAN) with a Market Outperform. PT $5.00.
The firm comments, "We are initiating coverage on Prana Biotechnology, that is developing a platform technology to address the potential causes of neurodegenerative disorders. Prana is undervalued relative to its peer group, in our view."
"We believe that Prana could be valued at par with the average of a comparable group of drug developers with multiple Phase 2 assets, which trade at an enterprise value of $174MM."
For an analyst ratings summary and ratings history on Prana Biotechnology click here. For more ratings news on Prana Biotechnology click here.
Shares of Prana Biotechnology closed at $2.18 yesterday.
The firm comments, "We are initiating coverage on Prana Biotechnology, that is developing a platform technology to address the potential causes of neurodegenerative disorders. Prana is undervalued relative to its peer group, in our view."
"We believe that Prana could be valued at par with the average of a comparable group of drug developers with multiple Phase 2 assets, which trade at an enterprise value of $174MM."
For an analyst ratings summary and ratings history on Prana Biotechnology click here. For more ratings news on Prana Biotechnology click here.
Shares of Prana Biotechnology closed at $2.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Starts Intrepid Potash (IPI) at Buy
- Berenberg Starts Bridgepoint Group PLC (BPT:LN) at Buy
- Lucid Capital Markets Starts Blue Owl Capital Corp. (OBDC) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
